When is ACAD's latest earnings report released?
The most recent financial report for Acadia pharmaceuticals inc. (ACAD) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ACAD's short-term business performance and financial health. For the latest updates on ACAD's earnings releases, visit this page regularly.
Where does ACAD fall in the P/E River chart?
According to historical valuation range analysis, Acadia pharmaceuticals inc. (ACAD)'s current price-to-earnings (P/E) ratio is 10.89, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
What is the operating profit of ACAD?
According to the latest financial report, Acadia pharmaceuticals inc. (ACAD) reported an Operating Profit of 17.39M with an Operating Margin of 6.12% this period, representing a decline of 88.67% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is ACAD's revenue growth?
In the latest financial report, Acadia pharmaceuticals inc. (ACAD) announced revenue of 283.99M, with a Year-Over-Year growth rate of 9.39%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much cash does ACAD have?
At the end of the period, Acadia pharmaceuticals inc. (ACAD) held Total Cash and Cash Equivalents of 185.54M, accounting for 0.12 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does ACAD go with three margins increasing?
In the latest report, Acadia pharmaceuticals inc. (ACAD) achieved the “three margins increasing” benchmark, with a gross margin of 90.8%%, operating margin of 6.12%%, and net margin of 96.3%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess ACAD's profit trajectory and future growth potential.
Is ACAD's EPS continuing to grow?
According to the past four quarterly reports, Acadia pharmaceuticals inc. (ACAD)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 1.62. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of ACAD?
Acadia pharmaceuticals inc. (ACAD)'s Free Cash Flow (FCF) for the period is -52.74M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 232.08% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of ACAD?
The latest valuation data shows Acadia pharmaceuticals inc. (ACAD) has a Price-To-Earnings (PE) ratio of 10.89 and a Price/Earnings-To-Growth (PEG) ratio of 0.01. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.
